Status:
UNKNOWN
Effect of Apollo Wearable on Long COVID-19 Symptoms.
Lead Sponsor:
The Board of Medicine
Collaborating Sponsors:
Apollo Neuroscience, Inc.
Conditions:
Post-acute Sequelae of SARS-COV-2 Infection
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to examine how Apollo wearable use impacts symptoms and quality of life following long COVID.
Detailed Description
Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as long-COVID, is a syndrome that describes the persistence of symptoms or other sequelae weeks or months after initial SARS-CoV-2 infect...
Eligibility Criteria
Inclusion
- New purchasers of Apollo who haven't started using their Apollo device or previous users of Apollo who haven't used Apollo in the preceding 14 days.
- Age 18 years or over
- Currently experiencing symptoms related to long-COVID according to PASC (self report).
- Must be experiencing PASC symptoms in at least one of the following domains:
- Respiratory-related symptoms Fatigue-related symptoms Neurologic-related symptoms Psychiatric-related symptoms Sleep-related symptoms Change in quality of life/functional status
Exclusion
- Inability to use or access a compatible Android or iOS smartphone
- Are unable to complete consent and questionnaires written in English
- Current resident of a European Union (EU) country
Key Trial Info
Start Date :
October 23 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06097442
Start Date
October 23 2023
End Date
March 1 2025
Last Update
October 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Board of Medicine
Pittsburgh, Pennsylvania, United States, 15219